The U.S. Food and Drug Administration has issued a letter to Allergan (the makers of Latisse) stating that Allergan is in violation of the laws governing Latisse's approval for the lengthening, thickening, and darkening of lashes. In the letter, the FDA takes issue with the minimization and omission of risk information in the company's marketing materials and on the Latisse website.
Specifically, the issue is with Allergan's failure to mention the risk of hair growth outside of the intended margins, and of Allergan's failure to tell prospective users that they should not apply Laitsse to the lower lash line. The FDA's letter to Allergan also states their finding that the company has minimized the risk of increased permanent brown iris pigmentation with the use of Latisse.
In addition, the FDA has ruled that the FAQs page of the Latisse website is misleading when it comes to allergic reactions and possible infections which can be caused by contamination of the Latisse applicator.
Read the full text of the FDA's letter to Allergan about Latisse.
On the flipside, patient satisfaction so far appears to be high with Latisse, according to reviews and ratings posted on RealSelf.com.
Have you used Latisse? Do you feel the risks were represented accurately and prominently enough for you to make an informed decision about using it? Please share your experience.